Investor updates & Ad hoc announcements Keyword Search Clear 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 19 December 2018 Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumors more Published on: 19 December 2018 Chugai announed satralizumab receives FDA Breakthrough Therapy Designation for NMOSD more Published on: 19 December 2018 Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD more Published on: 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) more Published on: 10 December 2018 New member proposed for election to Roche Board of Directors more Published on: 10 December 2018 Changes to the Roche Corporate Executive Committee more Published on: 7 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer more Published on: 6 December 2018 Chugai Receives Orphan Drug Designation for TECENTRIQ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors more Published on: 6 December 2018 Chugai Presents Interim Analysis Data of Phase I/II Study of SKY59, anti-C5 antibody in PNH at ASH more Published on: 5 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more Published on: 5 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer more Published on: 4 December 2018 New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia more Published on: 3 December 2018 Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors more Published on: 3 December 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma more Published on: 27 November 2018 Reminder: Invitation to Roche’s live audio webcast at the 2018 American Society of Hematology’s 60 th Annual Meeting more Published on: 26 November 2018 FDA approves the ACTPen for Roche’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis more Published on: 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy more Published on: 13 November 2018 FDA grants priority review to Roche’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer more Published on: 1 November 2018 Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting more Published on: 1 November 2018 Invitation to Roche's live audio webcast at the 2018 American Society of Hematology's 60th Annual Meeting more Published on: 1 November 2018 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities more Published on: 1 November 2018 Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia more Published on: 29 October 2018 New STAIRWAY study data shows potential for extended durability with Roche’s faricimab in neovascular age-related macular degeneration (nAMD) more Published on: 24 October 2018 Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza more Published on: 22 October 2018 Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer more Published on: 22 October 2018 Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone more Published on: 21 October 2018 Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC) more Published on: 21 October 2018 Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours more Published on: 20 October 2018 Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer more Published on: 19 October 2018 FDA approves label update for Roche’s Mabthera/Rituxan (rituximab) in two rare forms of vasculitis more Published on: 17 October 2018 Roche reports very strong growth in the first nine months of 2018 more Published on: 16 October 2018 Reminder: Invitation to Roche's live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress more Published on: 15 October 2018 Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018 more Published on: 15 October 2018 Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research more Published on: 15 October 2018 Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more Published on: 10 October 2018 Reminder: Invitation to Roche's 9 Months Sales 2018 Audio Webcast and Conference Call more Published on: 10 October 2018 OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis more Published on: 9 October 2018 Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress more Published on: 4 October 2018 FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors more Published on: 4 October 2018 Invitation to Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress more Published on: 4 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 more Published on: 3 October 2018 Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress more Published on: 2 October 2018 Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS more Published on: 1 October 2018 FDA grants approval of Xolair (omalizumab) prefilled syringe formulation more Published on: 25 September 2018 Roche’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer more Published on: 24 September 2018 Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer more Published on: 24 September 2018 Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer more Published on: 24 September 2018 Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid more Published on: 21 September 2018 CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis more Published on: 21 September 2018 Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia more Published on: 18 September 2018 Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer more Published on: 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases more Published on: 17 September 2018 Invitation to Roche's 9 Months Sales 2018 Audio Webcast and Conference Call more Published on: 13 September 2018 FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis more Published on: 13 September 2018 Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running more Published on: 7 September 2018 Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine more Published on: 6 September 2018 Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC more Published on: 6 September 2018 Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) more Published on: 3 September 2018 Reminder: Invitation to Roche's Virtual Late Stage Pipeline Event 2018 more Published on: 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine more Published on: 29 August 2018 Launch of Gazyva for treatment of CD20-positive follicular lymphoma in Japan more Published on: 28 August 2018 Changes to the Roche Corporate Executive Committee more Published on: 22 August 2018 Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer more Published on: 20 August 2018 China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer more Published on: 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies more Published on: 3 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease more Published on: 31 July 2018 Roche Purchases Shares in Tender Offer for FMI more Published on: 30 July 2018 Invitation to Roche's Virtual Late Stage Pipeline Event 2018 more Published on: 27 July 2018 Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting more Published on: 26 July 2018 Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration more Published on: 26 July 2018 Roche reports very strong performance in the first half of 2018 more Published on: 24 July 2018 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more Published on: 23 July 2018 Roche receives CE Mark for its Accu-Chek Solo micropump system more Published on: 20 July 2018 Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer's Association International Conference more Published on: 20 July 2018 FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease more Published on: 19 July 2018 Reminder: Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call more Published on: 19 July 2018 Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer more Published on: 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) more Published on: 17 July 2018 Chugai to In-license ROS1/TRK Inhibitor Entrectinib more Published on: 17 July 2018 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more Published on: 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu more Published on: 12 July 2018 Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy more Published on: 11 July 2018 Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting more Published on: 3 July 2018 Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more Published on: 2 July 2018 Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash more Published on: 2 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer more Published on: 29 June 2018 Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome more Published on: 28 June 2018 Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call more Published on: 26 June 2018 FDA grants Priority Review to Roche’s baloxavir marboxil for the treatment of influenza more Published on: 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy more Published on: 22 June 2018 Changes to the Roche Enlarged Corporate Executive Committee more Published on: 19 June 2018 Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology more Published on: 15 June 2018 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan more Published on: 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis more Published on: 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery more Published on: 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia more Published on: 8 June 2018 FDA approves Roche’s MabThera/Rituxan (rituximab) for pemphigus vulgaris more Published on: 5 June 2018 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2018 more Published on: 5 June 2018 FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors more Published on: 3 June 2018 Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 2 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer more Published on: 1 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence more Published on: 1 June 2018 Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 29 May 2018 Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone more Published on: 25 May 2018 Reminder: Invitation to Roche Analyst Event at ASCO 2018 more Published on: 21 May 2018 Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors more Published on: 18 May 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress more Published on: 17 May 2018 Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death more Published on: 17 May 2018 Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel more Published on: 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis more Published on: 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress more Published on: 11 May 2018 Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress more Published on: 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer more Published on: 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more Published on: 7 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer more Published on: 27 April 2018 CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence more Published on: 26 April 2018 Roche reports a strong start in 2018 more Published on: 25 April 2018 Invitation to Roche Analyst Event at ASCO 2018 more Published on: 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis more Published on: 19 April 2018 Reminder: Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call more Published on: 18 April 2018 Launch of Tecentriq in 2L+ NSCLC in Japan more Published on: 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors more Published on: 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline more Published on: 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting more Published on: 6 April 2018 Roche completes acquisition of Flatiron Health more Published on: 28 March 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation more Published on: 27 March 2018 Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call more Published on: 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel more Published on: 22 March 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy more Published on: 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer more Published on: 14 March 2018 Save the date: Roche Analyst Event at ASCO 2018 more Published on: 13 March 2018 Roche Annual General Meeting 2018 more Published on: 8 March 2018 Changes to the Roche Enlarged Corporate Executive Committee more Published on: 27 February 2018 European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors more Published on: 15 February 2018 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer more Published on: 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris more Published on: 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema more Published on: 8 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. more Published on: 6 February 2018 Reminder: Invitation to Roche's Virtual Pipeline Event more Published on: 6 February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer more Published on: 1 February 2018 Roche reports good results in 2017 more Published on: 29 January 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder more Published on: 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors more Published on: 26 January 2018 Invitation to Roche's Virtual Pipeline Event more Published on: 24 January 2018 Reminder: Invitation to Roche's Full Year Results 2017 Presentation more Published on: 19 January 2018 TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC more Published on: 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis more Published on: 10 January 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash more Published on: 8 January 2018 Invitation to Roche's Full Year Results 2017 Presentation more Published on: 8 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment more Published on: 4 January 2018 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas more
Published on: 19 December 2018 Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumors more
Published on: 19 December 2018 Chugai announed satralizumab receives FDA Breakthrough Therapy Designation for NMOSD more
Published on: 19 December 2018 Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD more
Published on: 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) more
Published on: 7 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer more
Published on: 6 December 2018 Chugai Receives Orphan Drug Designation for TECENTRIQ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors more
Published on: 6 December 2018 Chugai Presents Interim Analysis Data of Phase I/II Study of SKY59, anti-C5 antibody in PNH at ASH more
Published on: 5 December 2018 Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more
Published on: 5 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer more
Published on: 4 December 2018 New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia more
Published on: 3 December 2018 Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors more
Published on: 3 December 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma more
Published on: 27 November 2018 Reminder: Invitation to Roche’s live audio webcast at the 2018 American Society of Hematology’s 60 th Annual Meeting more
Published on: 26 November 2018 FDA approves the ACTPen for Roche’s Actemra, a single-dose, prefilled autoinjector for the treatment of rheumatoid arthritis, giant cell arteritis and two forms of juvenile arthritis more
Published on: 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy more
Published on: 13 November 2018 FDA grants priority review to Roche’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer more
Published on: 1 November 2018 Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting more
Published on: 1 November 2018 Invitation to Roche's live audio webcast at the 2018 American Society of Hematology's 60th Annual Meeting more
Published on: 1 November 2018 Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities more
Published on: 1 November 2018 Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia more
Published on: 29 October 2018 New STAIRWAY study data shows potential for extended durability with Roche’s faricimab in neovascular age-related macular degeneration (nAMD) more
Published on: 24 October 2018 Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza more
Published on: 22 October 2018 Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer more
Published on: 22 October 2018 Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone more
Published on: 21 October 2018 Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC) more
Published on: 21 October 2018 Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours more
Published on: 20 October 2018 Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer more
Published on: 19 October 2018 FDA approves label update for Roche’s Mabthera/Rituxan (rituximab) in two rare forms of vasculitis more
Published on: 16 October 2018 Reminder: Invitation to Roche's live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress more
Published on: 15 October 2018 Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018 more
Published on: 15 October 2018 Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research more
Published on: 15 October 2018 Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment more
Published on: 10 October 2018 Reminder: Invitation to Roche's 9 Months Sales 2018 Audio Webcast and Conference Call more
Published on: 10 October 2018 OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis more
Published on: 9 October 2018 Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress more
Published on: 4 October 2018 FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors more
Published on: 4 October 2018 Invitation to Roche’s live audio webcast at the 2018 European Society for Medical Oncology (ESMO) Congress more
Published on: 4 October 2018 Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018 more
Published on: 3 October 2018 Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress more
Published on: 2 October 2018 Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS more
Published on: 1 October 2018 FDA grants approval of Xolair (omalizumab) prefilled syringe formulation more
Published on: 25 September 2018 Roche’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer more
Published on: 24 September 2018 Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer more
Published on: 24 September 2018 Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer more
Published on: 24 September 2018 Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid more
Published on: 21 September 2018 CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis more
Published on: 21 September 2018 Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia more
Published on: 18 September 2018 Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer more
Published on: 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases more
Published on: 17 September 2018 Invitation to Roche's 9 Months Sales 2018 Audio Webcast and Conference Call more
Published on: 13 September 2018 FDA approves subcutaneous formulation of Actemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis more
Published on: 13 September 2018 Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running more
Published on: 7 September 2018 Baloxavir Marboxil Phase II and III Studies for the Treatment of Influenza Published in the New England Journal of Medicine more
Published on: 6 September 2018 Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC more
Published on: 6 September 2018 Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) more
Published on: 3 September 2018 Reminder: Invitation to Roche's Virtual Late Stage Pipeline Event 2018 more
Published on: 30 August 2018 Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine more
Published on: 29 August 2018 Launch of Gazyva for treatment of CD20-positive follicular lymphoma in Japan more
Published on: 22 August 2018 Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer more
Published on: 20 August 2018 China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer more
Published on: 13 August 2018 FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies more
Published on: 3 August 2018 PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease more
Published on: 27 July 2018 Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting more
Published on: 26 July 2018 Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration more
Published on: 24 July 2018 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more
Published on: 20 July 2018 Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer's Association International Conference more
Published on: 20 July 2018 FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease more
Published on: 19 July 2018 Reminder: Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call more
Published on: 19 July 2018 Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer more
Published on: 18 July 2018 FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) more
Published on: 17 July 2018 Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more
Published on: 17 July 2018 Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu more
Published on: 12 July 2018 Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy more
Published on: 11 July 2018 Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting more
Published on: 3 July 2018 Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018 more
Published on: 2 July 2018 Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash more
Published on: 2 July 2018 Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer more
Published on: 29 June 2018 Roche’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome more
Published on: 28 June 2018 Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call more
Published on: 26 June 2018 FDA grants Priority Review to Roche’s baloxavir marboxil for the treatment of influenza more
Published on: 25 June 2018 Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy more
Published on: 19 June 2018 Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology more
Published on: 15 June 2018 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan more
Published on: 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis more
Published on: 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery more
Published on: 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia more
Published on: 8 June 2018 FDA approves Roche’s MabThera/Rituxan (rituximab) for pemphigus vulgaris more
Published on: 5 June 2018 Save the date: Roche Analyst Event on Diagnostics Division at AACC 2018 more
Published on: 5 June 2018 FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors more
Published on: 3 June 2018 Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 2 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer more
Published on: 1 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence more
Published on: 1 June 2018 Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 29 May 2018 Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone more
Published on: 21 May 2018 Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors more
Published on: 18 May 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress more
Published on: 17 May 2018 Follow-up phase III data showed Roche’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death more
Published on: 17 May 2018 Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel more
Published on: 15 May 2018 FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis more
Published on: 14 May 2018 Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress more
Published on: 11 May 2018 Invitation to Roche’s Virtual Pipeline Event from WFH 2018 World Congress more
Published on: 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer more
Published on: 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting more
Published on: 7 May 2018 FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer more
Published on: 27 April 2018 CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence more
Published on: 23 April 2018 New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis more
Published on: 19 April 2018 Reminder: Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call more
Published on: 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors more
Published on: 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline more
Published on: 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting more
Published on: 28 March 2018 Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation more
Published on: 27 March 2018 Invitation to Roche’s First Quarter Sales 2018 Audio Webcast and Conference Call more
Published on: 26 March 2018 Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel more
Published on: 22 March 2018 FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy more
Published on: 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer more
Published on: 27 February 2018 European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors more
Published on: 15 February 2018 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer more
Published on: 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris more
Published on: 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema more
Published on: 6 February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer more
Published on: 29 January 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder more
Published on: 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors more
Published on: 24 January 2018 Reminder: Invitation to Roche's Full Year Results 2017 Presentation more
Published on: 19 January 2018 TECENTRIQ approved in Japan for the treatment of unresectable, advanced or recurrent NSCLC more
Published on: 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis more
Published on: 10 January 2018 Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash more
Published on: 8 January 2018 Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment more
Published on: 4 January 2018 Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas more